![featured-image](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482904472/image_1482904472.jpg?io=getty-c-w750)
Mario Tama Denmark's drug regulator has asked the European Medicine Agency's safety committee to evaluate two studies that found a potential link between Novo Nordisk's ( NVO ) type 2 diabetes drug Ozempic (semaglutide) and a rare eye condition. The Danish Medicines Agency said.